XENT Stock Overview
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States.
Intersect ENT Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$28.24|
|52 Week High||US$28.25|
|52 Week Low||US$15.92|
|1 Month Change||0.89%|
|3 Month Change||3.33%|
|1 Year Change||59.91%|
|3 Year Change||9.42%|
|5 Year Change||24.13%|
|Change since IPO||118.58%|
Recent News & Updates
|XENT||US Medical Equipment||US Market|
Return vs Industry: XENT exceeded the US Medical Equipment industry which returned -17.5% over the past year.
Return vs Market: XENT exceeded the US Market which returned -10.8% over the past year.
|XENT Average Weekly Movement||0.9%|
|Medical Equipment Industry Average Movement||10.6%|
|Market Average Movement||8.0%|
|10% most volatile stocks in US Market||17.0%|
|10% least volatile stocks in US Market||3.0%|
Stable Share Price: XENT is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 1% a week.
Volatility Over Time: XENT's weekly volatility (1%) has been stable over the past year.
About the Company
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries.
Intersect ENT Fundamentals Summary
|XENT fundamental statistics|
Is XENT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|XENT income statement (TTM)|
|Cost of Revenue||US$29.25m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-4.98|
|Net Profit Margin||-161.94%|
How did XENT perform over the long term?See historical performance and comparison
Is Intersect ENT undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
In this section, we usually try to help investors determine whether Intersect ENT is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Intersect ENT has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
How is Intersect ENT forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XENT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: XENT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: XENT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: XENT's revenue (24.2% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: XENT's revenue (24.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if XENT's Return on Equity is forecast to be high in 3 years time
How has Intersect ENT performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: XENT is currently unprofitable.
Growing Profit Margin: XENT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: XENT is unprofitable, and losses have increased over the past 5 years at a rate of 45.3% per year.
Accelerating Growth: Unable to compare XENT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XENT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (19.1%).
Return on Equity
High ROE: XENT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Intersect ENT's financial position?
Financial Health Score1/6
Financial Health Score 1/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: XENT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: XENT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: XENT has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: XENT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: XENT has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: XENT has sufficient cash runway for 2.8 years if free cash flow continues to reduce at historical rates of 24.4% each year.
What is Intersect ENT current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate XENT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate XENT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if XENT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if XENT's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as XENT has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tom West (57 yo)
Mr. Thomas A. West, also known as Tom, is an Independent Director at Orthofix Medical Inc. since December 2021. He has been President, Chief Executive Officer and Director of Intersect ENT, Inc. since July...
CEO Compensation Analysis
Compensation vs Market: Tom's total compensation ($USD6.28M) is above average for companies of similar size in the US market ($USD3.90M).
Compensation vs Earnings: Tom's compensation has increased whilst the company is unprofitable.
Experienced Management: XENT's management team is considered experienced (2.5 years average tenure).
Experienced Board: XENT's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2%.
Intersect ENT, Inc.'s employee growth, exchange listings and data sources
- Name: Intersect ENT, Inc.
- Ticker: XENT
- Exchange: NasdaqGM
- Founded: 2003
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$954.900m
- Shares outstanding: 33.81m
- Website: https://www.intersectent.com
Number of Employees
- Intersect ENT, Inc.
- 1555 Adams Drive
- Menlo Park
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/13 00:00|
|End of Day Share Price||2022/05/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.